Obsidian Therapeutics, Inc. (OBX) Income Statement
OBX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOBX revenue and net income
OBX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OBX quarterly EPS vs estimates
OBX income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $86.1M | $73.2M |
| Sales, general & admin | $19.6M | $18.1M |
| Total operating expenses | $105.7M | $91.3M |
| Operating income | −$105.7M | −$91.3M |
| Interest income | $5.1M | $8.1M |
| Income before taxes | −$100.6M | −$83.1M |
| Net income | −$100.6M | −$83.1M |
| EBITDA | −$104.2M | −$89.7M |
| EPS (diluted) | $345.33 | — |
| Mar '26 | Mar '25 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $15.7M | $21.1M |
| Sales, general & admin | $4.5M | $5.5M |
| Total operating expenses | $20.3M | $26.6M |
| Operating income | −$20.3M | −$26.6M |
| Interest income | $647,000 | $1.6M |
| Income before taxes | −$19.6M | −$25.0M |
| Net income | −$19.6M | −$25.0M |
| EBITDA | −$19.9M | −$26.2M |
| EPS (diluted) | −$3.26 | −$3.23 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OBX's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OBX financial results
Obsidian Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $100.6 million. Diluted earnings per share came to $345.33.
See the OBX stock overview for the latest quote and news, or the OBX chart for price history and technical indicators.
OBX income statement FAQ
Does Obsidian Therapeutics have revenue?
Obsidian Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Obsidian Therapeutics profitable?
No. Obsidian Therapeutics reported a net loss of $100.6 million in fiscal 2025.
How much does Obsidian Therapeutics spend on research and development?
Obsidian Therapeutics spent $86.1 million on research and development in fiscal 2025.
What are Obsidian Therapeutics's earnings per share?
Obsidian Therapeutics earned $345.33 per diluted share in fiscal 2025.
When does Obsidian Therapeutics's fiscal year end?
Obsidian Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.